New peptide drug shows promise for obesity and diabetes in early trial

NCT ID NCT04838405

Completed Disease control Sponsor: Carmot Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called CT-388 in 129 overweight or obese adults, including some with type 2 diabetes. The study aimed to check the drug's safety and how the body processes it, while also measuring weight loss and blood sugar changes. Participants received either CT-388 or a placebo by injection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CT-388 (a synthetic peptide)
What this could lead to: If successful, CT-388 could become a new treatment for obesity and type 2 diabetes, helping with weight loss and blood sugar control.
What could go wrong: This is an early Phase 1 trial focused on safety, so it is too soon to know if CT-388 works. Side effects are possible, and the results may not lead to an approved treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES

Contacts and locations

Locations

Carmot Clinical Research Unit 101

Perth, Western Australia, 6009, Australia
Carmot Clinical Research Unit 105

Monterrey, Nuevo León, 66260, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.